Supplementary Figure 1D showed that there was no significant difference in PDI signature between classical and mesenchymal subtypes. Further, there were statistical differences observed in the groups divided by subtype (CL+ME vs. NE+PN), 1p19q codel status, IDH status in TCGA LGG and/or GBM cohort. However, there was no significant difference in the MGMT promoter status and IDH status in the TCGA GBM cohort (Supplementary Figure 1E–1J). The gene discussed is IDH1; the disease is glioblastoma.